Press Releases

Date Title and Summary Additional Formats
Toggle Summary NewLink Genetics Announces Oral Presentation at the 2018 American Society of Hematology (ASH) Annual Meeting
AMES, Iowa , Nov. 01, 2018 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (NASDAQ:NLNK) announced today that an abstract with data pertaining to the use of the Company's investigational immuno-oncology molecule, indoximod, in combination therapy for patients with newly diagnosed acute myeloid
View HTML
Toggle Summary NewLink Genetics to Participate in the Stifel 2018 Healthcare Conference
AMES, Iowa , Oct. 30, 2018 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (NASDAQ:NLNK), a clinical stage biopharmaceutical company focused on developing novel immuno-oncology therapeutic candidates, announced today it will present at the Stifel 2018 Healthcare Conference.
View HTML
Toggle Summary NewLink Genetics to Host Its Third Quarter 2018 Financial Results Conference Call on November 1, 2018
AMES, Iowa , Oct. 18, 2018 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (NASDAQ:NLNK) today announced that it will release its third quarter 2018 financial results on Thursday, November 1, 2018. The company has scheduled a conference call for 4:30 PM ET the same day to discuss the results and
View HTML
Toggle Summary NewLink Genetics Announces Indoximod Biomarker Data and Prodrug NLG802 Pharmacokinetic Data to be Presented at SITC 2018
AMES, Iowa , Oct. 01, 2018 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (NASDAQ:NLNK) announced today that two abstracts were accepted for presentation at the Society for Immunotherapy of Cancer ( SITC ) 33 rd Annual Meeting being held November 7-11, 2018 in Washington , D.C.  These poster
View HTML
Toggle Summary NewLink Genetics to Participate in the Cantor Global Healthcare Conference
AMES, Iowa , Sept. 18, 2018 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (NASDAQ:NLNK) announced today that the Company will present at the 2018 Cantor Global Healthcare Conference on Wednesday, October 3, 2018 , at 4:00PM ET in New York, New York .
View HTML
Toggle Summary NewLink Genetics to Participate in the Baird Global Healthcare Conference
AMES, Iowa , Aug. 21, 2018 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (NASDAQ:NLNK) announced today that the company will present at the 2018 Baird Global Healthcare Conference on Wednesday, September 5, 2018 , at 11:25AM ET .  A live webcast of the presentation will be available on the
View HTML
Toggle Summary NewLink Genetics Announces Clinical Plan, Reports Second Quarter 2018 Financial Results and Revises Cash Guidance
Management to Host Conference Call Today at 4:30 p.m. ET AMES, Iowa , July 31, 2018 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation  (NASDAQ:NLNK) today announced its clinical plan and strategy, reported consolidated financial results for the second quarter of 2018, and revised its cash guidance.
View HTML
Toggle Summary NewLink Genetics to Host Its Second Quarter 2018 Financial Results Conference Call on July 31, 2018
AMES, Iowa , July 10, 2018 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation  (NASDAQ:NLNK) today announced that it will release its second quarter 2018 financial results on Tuesday, July 31, 2018. The company has scheduled a conference call for 4:30 PM ET the same day to discuss these results and
View HTML
Toggle Summary NewLink Genetics Announces Positive Updated Phase 1 Data with Indoximod Plus Radio-Immunotherapy for Pediatric Patients with DIPG Presented at ISPNO 2018
AMES, Iowa --(BUSINESS WIRE)--Jul. 2, 2018-- NewLink Genetics Corporation (NASDAQ:NLNK), reported that updated Phase 1 data  evaluating indoximod plus front-line radiation and maintenance chemotherapy for the treatment of pediatric patients with newly diagnosed diffuse intrinsic pontine glioma
View HTML
Toggle Summary NewLink Genetics Announces Updated Data for Indoximod Plus Radio-Immunotherapy in DIPG to be Presented at ISPNO 2018 Meeting
AMES, Iowa , June 20, 2018 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (NASDAQ:NLNK) today announced that updated data for patients with diffuse intrinsic pontine glioma (DIPG) from NLG2105 , a Phase 1 study evaluating indoximod in combination with radiation and chemotherapy for the treatment
View HTML